Effect of low‐dose bortezomib on bone formation in smouldering multiple myelomaGerhard Hildebrandt, Maurizio Zangari, Tamara Berno et al.|British Journal of Haematology|2018Cited by 3
Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple MyelomaSagar Lonial, Shaji Kumar, Moshe Levy et al.|Blood|2021Cited by 3